Panama buys 3 million doses of the vaccine "Sputnik of V"

Panama decided to buy 3 million doses of the Russian vaccine against COVID-19 coronavirus to impart about a half of the population of the country. The corresponding letter the ministry sent health care of Panama to the Russian Direct Investment Fund (RDIF) which supervises questions of promotion of medicine abroad.

Our geographical location does us by one of the most important centers of air, land and sea traffic in the region and puts us at bigger risk, than other countries, says from which excerpts are given by Reuters agency.

In the letter it is also told that the government of Panama through the pharmaceutical and regulating authority is ready to grant the license for the emergency use of "Sputnik of V". The authorities of the country expect to receive vaccine by March, 2021.

Panama buys 3 million doses of vaccine from COVID-19 "Sputnik of V"

As notes news agency, Panama is registered by one of the highest rates of a disease of a koronavirusny infection in Central America. As of February 4, 2021, in Panama where more than 4 million people live, 324.5 thousand cases of infection of COVID-19 from which 1.1 thousand — in the last 24 hours were revealed. In total in the country from effects of infection 5.4 thousand people, 23 — for the last day died.

At the beginning of 2021 the authorities of Panama announced selection of $56 million for purchase in total 5.5 million doses of vaccines against a coronavirus approximately for 80% of the population. Then it was not specified what vaccines are going to be purchased.

RDIF repeatedly said that the price of "Sputnik of V" for foreign countries will be close to $10. Therefore purchase of 3 million doses of medicine can cost Panama $30 million.

At the beginning of 2021 some countries reconsidered the relation to the vaccine "Sputnik of V" also because of interruptions in deliveries by the approved vaccine of Pfizer. The producer reported in the middle of January that he will temporarily reduce supply of medicine to the EU due to the need to increase production capacities for more large-scale release — to 2 million doses a year.^[1]

Notes